ÄÁÅÙÃ÷»ó¼¼º¸±â

½Å»ý¾Æ¿Í À¯¾Æ¿¡°Ô ³ªÅ¸³ª´Â Äڷγª-19 ¹ÙÀÌ·¯½º Áø´Ü¿¬±¸
½Å»ý¾Æ¿Í À¯¾Æ¿¡°Ô ³ªÅ¸³ª´Â Äڷγª-19 ¹ÙÀÌ·¯½º Áø´Ü¿¬±¸
  • ÀúÀÚDomenico Umberto De Rose, Fiammetta Piersigilli,Maria Paola Ronchetti, Alessandra Santisi,¿Ü
  • ÃâÆÇ»ç¾ÆÁø
  • ÃâÆÇÀÏ2020-07-12
  • µî·ÏÀÏ2020-12-21
º¸À¯ 1, ´ëÃâ 0, ¿¹¾à 0, ´©Àû´ëÃâ 6, ´©Àû¿¹¾à 0

Ã¥¼Ò°³

Recently, an outbreak of viral pneumonitis in Wuhan, Hubei, China successively
spread as a global pandemia, led to the identification of a novel betacoronavirus
species, the 2019 novel coronavirus, successively designated 2019-nCoV then
SARS-CoV-2). The SARS-CoV-2 causes a clinical syndrome designated coronavirus
disease 2019 (COVID19) with a spectrum of manifestations ranging from mild upper
respiratory tract infection to severe pneumonitis, acute respiratory distress
syndrome (ARDS) and death. Few cases have been observed in children and
adolescents who seem to have a more favorable clinical course than other age
groups, and even fewer in newborn babies. This review provides an overview of
the knowledge on SARS-CoV-2 epidemiology, transmission, the associated clinical
presentation and outcomes in newborns and infants up to 6 months of life.

¸ñÂ÷

Á¦ 1Æí Äڷγª¹ÙÀÌ·¯½º Á¤ÀÇ
1. Äڷγª¹ÙÀÌ·¯½º°¨¿°Áõ-19(Covid-19) Á¤º¸ 7
2. Äڷγª¹ÙÀÌ·¯½º ºÐ·ù ¹× Æ¯¼º 9
3. Äڷγª¹ÙÀÌ·¯½º ÀüÀÚÇö¹Ì°æ ÇüÅ 11
4. Äڷγª¹ÙÀÌ·¯½º ±¸Á¶ (Covid-19 Organization) 13
5. Äڷγª19: È¯°æ¿¡ Áö¼ÓÀûÀΠ¿µÇâÀ» ¹ÌÄ¥±î? 19
6. Ä¡·á¹ý(Therapeutical Method) 22

Á¦ 2Æí ¿¬±¸³í¹®
Novel Coronavirus disease (COVID-19) in newborns and
infants: what we know so far

1. Introduction 23
2. Methods 24
3. SARS, coronaviruses and children 24
4. Diagnosis 25
5. Maternal-foetal transmission and breastfeeding 25
6. Clinical features in newborns and infants 27
7. Infection control and treatment 27
8. Conclusions 28
9. References 29

ÇÑÁÙ ¼­Æò